Moderna for cell therapies: Like Moderna uses mRNA to develop vaccines and treatments, Lineage Cell Therapeutics is developing new cell-based therapies for degenerative diseases and cancer.

CRISPR Therapeutics for cell replacement: Similar to how CRISPR Therapeutics uses gene editing to target diseases, Lineage Cell Therapeutics is working on fundamental biological repairs using cell replacement therapies for conditions like spinal cord injury and macular degeneration.

A clinical-stage Gilead Sciences focused on regenerative medicine: Like Gilead aims to develop groundbreaking treatments for severe diseases, Lineage Cell Therapeutics is tackling currently untreatable degenerative conditions and cancers with novel cell therapies, but is still in early clinical stages.

```html

• OpRegen: A retinal pigment epithelium cell replacement therapy designed for the treatment of dry age-related macular degeneration.
• OPC1: An oligodendrocyte progenitor cell therapy developed to treat acute spinal cord injuries.
• VAC2: An allogeneic cancer immunotherapy utilizing antigen-presenting dendritic cells for non-small cell lung cancer.
• Renevia: A product offered for facial aesthetics.

```

Lineage Cell Therapeutics (LCTX) is primarily a clinical-stage biotechnology company focused on the research and development of novel cell therapies. As such, most of its pipeline products (OpRegen, OPC1, VAC2) are currently in clinical trials and are not yet commercially available for sale to customers. Therefore, the company does not have major commercial customers for these investigational therapies in the traditional sense.

The company does, however, offer Renevia, a facial aesthetics product. For Renevia, Lineage Cell Therapeutics primarily sells to other companies and professional practices in the medical aesthetics industry. These customer categories include:

• Dermatology Clinics and Practices
• Plastic Surgery Clinics and Practices
• Medical Spas (MedSpas)

null

Brian Culley, Chief Executive Officer

Brian Culley was appointed Chief Executive Officer and a director of Lineage Cell Therapeutics in September 2018. He also twice served as Interim Chief Financial Officer (Jan–Jun 2021 and Jul–Nov 2022). Mr. Culley possesses over 30 years of business and scientific experience within the life sciences industry. Prior to joining Lineage, he was the interim Chief Executive Officer at Artemis Therapeutics, Inc. from August 2017 to September 2018. From 2010, Mr. Culley served as Chief Executive Officer of Mast Therapeutics, Inc., and was also a member of its board of directors from 2011, until the company's merger with Savara, Inc. in April 2017. His earlier career also included roles at Immusol, Inc., and Neurocrine Biosciences, Inc. He holds a B.S. in Biology, an M.S. in Biochemistry & Molecular Biology, and an MBA.

Jill Howe, Chief Financial Officer

Jill Howe joined Lineage as Chief Financial Officer on November 14, 2022. She brings over 20 years of extensive strategic, financial, and operational experience to the company, with a focus on capital strategy, corporate finance, treasury management, and global infrastructure. Ms. Howe has played key roles in building biotechnology organizations and implementing operational infrastructures, including executing over $1.66 billion in capital raising transactions. Most recently, she served as Chief Financial Officer of DTx Pharma. From 2018 to 2021, she was the Vice President of Finance and Treasurer for Gossamer Bio, Inc., where she was instrumental in the company's initial public offering and subsequent listings and debt deals. Ms. Howe's background also includes serving as Controller & Director of Finance at Amplyx Pharmaceuticals, Inc., which was later acquired by Pfizer, Inc. She held a similar role at Receptos, Inc., which was acquired by Celgene, Inc. for more than $7 billion.

George Samuel, General Counsel and Corporate Secretary

George Samuel serves as the General Counsel and Corporate Secretary for Lineage Cell Therapeutics. Before joining Lineage, Mr. Samuel was the Director, Senior Counsel for Lytx, Inc., managing commercial legal operations for an international video telematics SaaS company from January 2020 to August 2021. Prior to that, he practiced corporate law at VLP Law Group LLC. From August 2016 to February 2019, he held the position of VP, General Counsel and Corporate Secretary for Cardiff Oncology, Inc., a clinical-stage biotechnology company focused on oncology treatments.

The key risks to Lineage Cell Therapeutics (LCTX) primarily revolve around the inherent challenges of a clinical-stage biotechnology company developing novel cell therapies. These include the success of its clinical pipeline, its financial stability, and regulatory and manufacturing compliance.

1. Clinical Trial Success and Regulatory Approval

   As a clinical-stage biotechnology company, Lineage Cell Therapeutics's valuation and future prospects are heavily dependent on the successful advancement and ultimate regulatory approval of its cell therapy candidates, including OpRegen, OPC1, and VAC2. The clinical development process is lengthy, expensive, and uncertain, with a high rate of attrition at various stages. Even if trials yield favorable results, the data is subject to varying interpretations and regulatory changes that could delay, limit, or prevent approvals. Furthermore, even post-approval, the company may face extensive obligations or unforeseen side effects that could lead to limitations, recalls, or withdrawal of approval.

2. Financial Health and Funding

   Lineage Cell Therapeutics operates with a significant cash burn rate, reporting substantial net losses and negative operating margins. While the company's cash position is projected to fund operations into Q2 2027, this runway is finite. Any unexpected delays in clinical trials or increases in research and development costs could shorten this timeline, necessitating further dilutive capital raises. The company's Altman Z-Score, a measure of bankruptcy probability, places it in the distress zone, implying a potential risk of bankruptcy within the next two years. The need for continuous funding, largely through equity, makes the company susceptible to market conditions and investor sentiment.

3. Regulatory Compliance and Manufacturing Challenges

   Lineage Cell Therapeutics faces specific regulatory risks related to its reliance on pluripotent cell lines, which may not align with current donor eligibility standards. This could lead to requirements for special labeling, additional conditions, or limitations on the use of its products. Addressing these compliance challenges might necessitate further studies or enhanced controls, potentially impacting the business. Additionally, the company's cell banking and product manufacturing for its cell therapy candidates are conducted by a subsidiary in Jerusalem, Israel, introducing a geopolitical risk due to the ongoing regional conflict, which could materially and adversely impact these critical manufacturing processes.

null

Lineage Cell Therapeutics (LCTX) develops cell therapies for degenerative diseases. The addressable markets for its main products are substantial. For OpRegen, a retinal pigment epithelium cell replacement therapy for dry age-related macular degeneration (AMD), the global market for dry age-related macular degeneration was valued at approximately USD 5.27 billion in 2024 and is projected to reach USD 10.58 billion by 2032. The North American market held the largest share in 2024, at 46.3%. For OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, the global acute spinal cord injury market size was valued at USD 7.03 billion in 2024 and is projected to grow to USD 10.09 billion by 2033. Another estimate places the global market at USD 7.98 billion in 2024, expected to reach USD 12.16 billion by 2032. North America is the most significant global acute spinal cord injury market shareholder. For VAC2, an allogeneic cancer immunotherapy for non-small cell lung cancer (NSCLC), the global non-small cell lung cancer market was estimated at USD 20.2 billion in 2024 and is expected to grow to USD 53.9 billion by 2034. The global non-small cell lung cancer (NSCLC) therapeutics market was valued at USD 38.49 billion in 2025 and is projected to grow to USD 74.99 billion by 2034. North America dominated this market with a 44.4% market share in 2024. The U.S. non-small cell lung cancer market alone was valued at USD 8.2 billion in 2024.

For Lineage Cell Therapeutics (LCTX), several key drivers are expected to fuel future revenue growth over the next 2-3 years, primarily stemming from the advancement of its cell therapy pipeline and strategic collaborations.

1. Milestone Payments and Future Royalties from OpRegen (RG6501) Collaboration with Roche/Genentech: Lineage's lead program, OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy for dry age-related macular degeneration, is under a substantial worldwide collaboration with Roche and Genentech. The company has already received significant upfront and development milestone payments and is eligible for up to $615 million in additional milestones, plus tiered double-digit royalties upon commercialization. Recent activity, such as the expansion of OpRegen clinical sites for the GALE Phase 2a study by Roche/Genentech, with 10 new sites opened in the last nine months (as of March 2026), indicates continued progression and a positive outlook for the program, which could trigger further milestone revenue.
2. Expansion of Collaboration and Development Programs (e.g., ANP1, Islet Cell Initiative, OPC1): Lineage is actively pursuing and securing new partnerships and advancing its diverse pipeline. This includes a research collaboration with William Demant Invest A/S (WDI) to fund the preclinical development of ReSonance (ANP1) for sensorineural hearing loss, which has already contributed to extending the company's cash runway. Additionally, the ongoing development of OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, continues to progress through clinical trials, with recent advancements in manufacturing and initial treatment of chronic SCI patients in the DOSED study. The company has also achieved an internal development milestone in its islet cell production initiative, aimed at addressing challenges in Type 1 Diabetes therapy, which could lead to future strategic partnerships and associated revenue streams.
3. Leveraging the AlloSCOPE™ Manufacturing Platform to Secure New Partnerships: Lineage's proprietary AlloSCOPE™ technology platform for the scalable and consistent manufacturing of "off-the-shelf" allogeneic cell therapies is a critical asset. The successful demonstration of cGMP production capabilities that could enable millions of doses from a single cell line strengthens its position as a leader in allogeneic cell process development. This advanced manufacturing capability not only supports its existing pipeline but also makes Lineage an attractive partner for other companies seeking to develop and produce cell therapies, potentially leading to new collaboration agreements, licensing deals, or contract manufacturing revenue.

Share Issuance

• Lineage Cell Therapeutics filed a prospectus supplement on March 11, 2026, for the potential offer and sale of its common shares having an aggregate offering price of up to $60 million.
• The company previously sold common shares with an aggregate gross sales price of over $22.58 million under prior prospectus supplements dated May 14, 2024, and November 12, 2025.
• Approximately $5.4 million in proceeds were received from warrant exercises in March 2026.

Inbound Investments

• The company achieved the first of the $620 million milestone payments available under its worldwide collaboration and license agreement with Roche and Genentech for the OpRegen cell therapy program.
• Lineage entered a research collaboration with William Demant Invest A/S (WDI) for its ReSonance program, with WDI expected to contribute up to $12 million of development costs over three years for preclinical development activities.